ClinicalTrials.gg

Program

lenbelintide

Also written as “AZD6234”, “Lenbelintide” and “AZD6234 solution for injection”.

Its studies are mostly in Obesity · Lymphoma, Follicular · Diabetes Mellitus, Type 2 · Renal Insufficiency · Overweight, led by AstraZeneca.

Furthest: phase 3, since Aug 5, 202616 company-led studies, 9 open or runningNext primary completion: Jan 29, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca169 open or runningphase 3since Aug 5, 2026Aug 19, 2022Jan 29, 2027phase 2 · NCT06151964
  • Named in AstraZeneca’s own pipeline as lenbelintide (AZD6234), phase 3, as of Oct 30, 2026 (source).

Also a collaborator on its studies: quotient-sciences and parexel.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 19, 2022First study: phase 1 study in OverweightFirst studyNCT05511025 · 54 enrolled · United States
  2. Sep 22, 2023Phase 2 study in OverweightNCT06151964 · 166 enrolled · Austria, Canada, Germany and more
  3. Nov 10, 2023Phase 1 study in OverweightNCT06132841 · 104 enrolled · United States, Japan
  4. Sep 11, 2024Phase 2 study in ObesityNCT06595238 · 262 enrolled · United States, Australia, Canada and more
  5. Feb 13, 20252 phase 2 studiesNCT06851858, NCT06862791
  6. Feb 24, 2025Phase 1 study in Renal InsufficiencyNCT06845813 · 24 enrolled · United States
  7. May 14, 2025Phase 2 study in ObesityNCT07017179 · 16 enrolled · China
  8. Jun 2, 2025Phase 1 study in ObesityNCT07013643 · 100 enrolled · United States
  9. Oct 23, 2025Phase 1 study in ObesityNCT07220954 · 19 enrolled · United Kingdom
  10. Mar 11, 2026Phase 1 study in Lymphoma, FollicularNCT07546760 · 28 planned · United States
  11. Aug 5, 20263 phase 3 studies in ObesityPhase 3 reachedNCT07784725, NCT07784270, NCT07776509
  12. Sep 29, 2026Primary completion moved from 2026-08-06 to 2026-10-23Date moved laterphase 2 · +3 months · NCT07017179
  13. Oct 13, 2026Phase 3 study in ObesityNCT07922330 · 330 planned · China, India
  14. Oct 26, 2026Phase 1 study in ObesityNCT07911514 · 60 planned · United Kingdom

Ahead

  1. Jan 29, 2027Primary completion: phase 2 study in OverweightNCT06151964
  2. Feb 4, 2027Primary completion: phase 1 study in Lymphoma, FollicularNCT07546760
  3. May 4, 2027Primary completion: phase 1 study in ObesityNCT07911514
  4. Jul 9, 2027Primary completion: phase 1 study in ObesityNCT07013643

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07911514Obesity · United Kingdom1Not yet recruitingMay 4, 202760
NCT07922330Obesity · China, India3Not yet recruitingSep 15, 2028330
NCT07776509Obesity · United States, Argentina, Brazil and more3RecruitingAug 9, 2028500
NCT07784270Obesity · United States, Argentina, Australia and more3RecruitingAug 9, 20281,500
NCT07784725Obesity · United States, Argentina, Australia and more3RecruitingAug 11, 20282,500
NCT07546760Lymphoma, Follicular · United States1RecruitingFeb 4, 202728
NCT07220954Obesity · United Kingdom1CompletedSep 16, 202619
NCT07013643Obesity · United States1Active, not recruitingJul 9, 2027100
NCT07017179Obesity · China2Active, not recruitingOct 23, 202616
NCT06845813Renal Insufficiency · United States1CompletedSep 30, 202524
NCT06862791Obesity · United States, Australia, Canada and more2CompletedMay 11, 2026377
NCT06851858Diabetes Mellitus, Type 2 · United States2CompletedMay 26, 202669
NCT06595238Obesity · United States, Australia, Canada and more2CompletedDec 3, 2025262
NCT06132841Overweight · United States, Japan1CompletedFeb 3, 2026104
NCT06151964Overweight · Austria, Canada, Germany and more2Active, not recruitingJan 29, 2027166
NCT05511025Overweight · United States1CompletedDec 19, 202354

How it is read

Names in the registry

  • “AZD6234”, 10 entries
  • “Lenbelintide”, 3 entries
  • “AZD6234 solution for injection”, 1 entry
  • “AZD9550 and AZD6234”, 1 entry
  • “AZD6234 Formulation 1”, 1 entry

Codes read as this program: AZD6234.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.